ZYME Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

19.49M

-37.19%

-0.324

+4.55%

24.20M

-10.72%

-0.095

-68.33%

28.12M

-42.28%

-0.253

-944.43%

Estimates Revision

The market is revising Downward the revenue expectations for Zymeworks Inc. (ZYME) for FY2025, with the revenue forecasts being adjusted by -15.34% over the past three months. During the same period, the stock price has changed by 38.00%.

Revenue Estimates for FY2025

Revise Downward

-15.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+22.51%

In Past 3 Month

Stock Price

Go Up

+38.00%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.10 USD with a low forecast of 25.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

35.10

High

42.00

Current: 0.000

Low

25.00

Averages

35.10

High

42.00

Truist

Asthika Goonewardene

Buy

initiated

$40

2025-12-17

Reason

Truist

Asthika Goonewardene

Price Target

$40

2025-12-17

initiated

Buy

Reason

Truist analyst Asthika Goonewardene initiated coverage of Zymeworks with a Buy rating and $40 price target. The firm says the company has shifted from a traditional platform-centric biotech to a royalty-focused business. Truist views zanidatamab and pasritamig as two potential blockbuster drugs that will generate "considerable" milestone and royalty income for Zymeworks. The company can also continue to leverage its leading drug development platform to create incremental value, the analyst tells investors in a research note.

Wells Fargo

Equal Weight

Overweight

upgrade

$25 -> $33

2025-12-12

Reason

Wells Fargo

Price Target

$25 -> $33

2025-12-12

upgrade

Equal Weight

Overweight

Reason

Wells Fargo upgraded Zymeworks to Overweight from Equal Weight with a price target of $33, up from $25. The firm believes the company's gastroesophageal adenocarcinoma could drive upside in the shares. Th readout could generate enthusing for Zymeworks' breast cancer opportunity, which Wells models at $1.5B and gives it a 55% probability of success.

Citizens JMP

Outperform

initiated

$32

2025-12-03

Reason

Citizens JMP

Price Target

$32

2025-12-03

initiated

Outperform

Reason

Citizens JMP initiated coverage of Zymeworks with an Outperform rating and $32 price target. The company's first internally developed product candidate, zanidatamab, was approved by the FDA, the analyst tells investors in a research note. The firm thinks Zanidatamab's second approval in gastroesophageal adenocarcinoma, expected in the second half of 2026, has a high likelihood of success.

B. Riley

Buy

maintain

$30 -> $40

2025-11-21

Reason

B. Riley

Price Target

$30 -> $40

2025-11-21

maintain

Buy

Reason

B. Riley raised the firm's price target on Zymeworks to $40 from $30 and keeps a Buy rating on the shares. Zymeworks' shift to a royalty-aggregation strategy aims to optimize future de-risked cash flows from partnered programs and the potential partnering of ZW191 in 2026, the analyst tells investors in a research note. By retaining in-house R&D, acquiring royalties rather than assets, and diversifying therapeutic exposure, the company reduces binary risk while maintaining scientific rigor, with a strengthened leadership team enhancing prospects for attractive, risk-adjusted shareholder returns, the firm says.

Leerink

Outperform

maintain

$37 -> $40

2025-11-19

Reason

Leerink

Price Target

$37 -> $40

2025-11-19

maintain

Outperform

Reason

Leerink raised the firm's price target on Zymeworks to $40 from $37 and keeps an Outperform rating on the shares after the company announced a strategic transformation from a traditional biotech into a revenue-generating royalty aggregator. The firm reiterated its Outperform rating given current valuation and its belief that the full HERIZON GEA-01 presentation will be a favorable catalyst. Additionally, current zani royalties/milestones represents roughly $29 in the firm's model, suggesting the stock is undervalued on zani fundamentals alone, the analyst tells investors in a research note.

Stifel

Stephen Willey

Buy

maintain

$30 -> $40

2025-11-19

Reason

Stifel

Stephen Willey

Price Target

$30 -> $40

2025-11-19

maintain

Buy

Reason

Stifel analyst Stephen Willey raised the firm's price target on Zymeworks (ZYME) to $40 from $30 and keeps a Buy rating on the shares. The firm is updating its model to reflect partner Jazz Pharmaceuticals' (JAZZ) disclosure of statistically-significant and clinically-meaningful topline results from the Phase 3 HERIZON-GEA-01 trial and Zyme's more-granular disclosure of those near-term regulatory milestone payments that are now likely-to-be-triggered following the trial success, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Zymeworks Inc (ZYME.O) is -28.70, compared to its 5-year average forward P/E of -3.99. For a more detailed relative valuation and DCF analysis to assess Zymeworks Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.99

Current PE

-28.70

Overvalued PE

14.99

Undervalued PE

-22.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

6.00

Current EV/EBITDA

216.60

Overvalued EV/EBITDA

45.90

Undervalued EV/EBITDA

-33.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

17.86

Current PS

20.84

Overvalued PS

44.38

Undervalued PS

-8.67

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ZYME News & Events

Events Timeline

No data

News

9.0

01-07NASDAQ.COM

PinnedZymeworks Reports Significant Survival Improvements in HERIZON Phase 3 Trial for Ziihera

9.0

14:03 PMNASDAQ.COM

ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis

9.0

01-07Benzinga

Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits

People Also Watch

Frequently Asked Questions

What is Zymeworks Inc (ZYME) stock price today?

The current price of ZYME is 23.35 USD — it has increased 1.08 % in the last trading day.

What is Zymeworks Inc (ZYME)'s business?

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

What is the price predicton of ZYME Stock?

What is Zymeworks Inc (ZYME)'s revenue for the last quarter?

Zymeworks Inc revenue for the last quarter amounts to 27.61M USD, increased 72.59 % YoY.

What is Zymeworks Inc (ZYME)'s earnings per share (EPS) for the last quarter?

Zymeworks Inc. EPS for the last quarter amounts to -0.26 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for Zymeworks Inc (ZYME)'s fundamentals?

How many employees does Zymeworks Inc (ZYME). have?

Zymeworks Inc (ZYME) has 280 emplpoyees as of January 09 2026.

What is Zymeworks Inc (ZYME) market cap?

Today ZYME has the market capitalization of 1.73B USD.